Guillain–Barré syndrome in a patient with renal cell carcinoma following the first course of pazopanib therapy

Sunitinib malate (Sutent, SU011248) is an oral multitargeted tyrosine kinase inhibitor (TKI) used for the treatment of metastatic renal cell carcinoma and imatinib (Gleevec)—resistant gastrointestinal stromal tumor (GIST) with few reported side effects including asthenia, myelosuppression, diarrhea, and mucositis. Scarce literature exists regarding the rare but often serious toxicities of sunitinib. Autoimmune and neurological side effects have been linked to sunitinib’s inhibition of VEGF receptors with a corresponding increase in VEGF levels, which is associated with development of different neuropathies. We hereby report an interesting case of Guillain-Barré syndrome in a middle-aged patient with metastatic renal cell carcinoma following sunitinib treatment.

Download Full-text

Poster 362: Nivolumab-Induced Concurrent Guillain-Barre Syndrome and Myasthenia Gravis in a Patient with Metastatic Renal Cell Carcinoma: A Case Report

PM&R ◽

10.1016/j.pmrj.2017.08.301 ◽

2017 ◽

Vol 9 ◽

pp. S246-S247 ◽

Cited By ~ 2

Author(s):

Isabel M. Rutzen-Lopez ◽

Jack B. Fu ◽

Jose E. Arias-Berrios

Keyword(s):

Renal Cell Carcinoma ◽

Case Report ◽

Myasthenia Gravis ◽

Cell Carcinoma ◽

Metastatic Renal Cell Carcinoma ◽

Renal Cell ◽

Guillain Barre Syndrome ◽

Guillain Barré Syndrome ◽

Guillain Barré

Download Full-text

Guillain-Barre syndrome: a typical paraneoplastic syndrome in a kidney transplant recipient with allograft renal cell carcinoma: a case report and review of the literature

BMC Nephrology ◽

10.1186/s12882-020-02095-y ◽

2020 ◽

Vol 21 (1) ◽

Author(s):

Izabela Zakrocka ◽

Iwona Baranowicz-Gąszczyk ◽

Agnieszka Korolczuk ◽

Wojciech Załuska

Keyword(s):

Renal Cell Carcinoma ◽

Kidney Transplantation ◽

Cell Carcinoma ◽

Kidney Transplant ◽

Renal Cell ◽

Guillain Barre Syndrome ◽

Renal Transplant Recipients ◽

Transplant Recipients ◽

Guillain Barré Syndrome ◽

Guillain Barré

Abstract Background Guillain-Barré syndrome (GBS) is an autoimmune polyneuropathy affecting the peripheral nervous system. This neurological disorder has been previously reported in bone marrow transplant recipients but is uncommon after kidney transplantation. Viral infections and calcineurin inhibitors are the main triggers of GBS in renal transplant recipients. Case presentation In this report, we present a case of a 47-year-old male patient 12 years after his second kidney transplantation who developed GBS due to papillary renal cell carcinoma. Infectious and drug-related origins of GBS were excluded. Despite intensive treatment, graftectomy was performed, after which neurological symptoms resolved. Conclusions In kidney transplant recipients, paraneoplastic aetiology should be considered in the differential diagnosis of GBS.

Download Full-text

Guillain-Barre Syndrome Caused by Tislelizumab and Axitinib

10.21203/rs.3.rs-564774/v1 ◽

2021 ◽

Author(s):

Yang Sun ◽

Yanjun Guo ◽

Yaqing Wu ◽

Ningning Luo ◽

Xinjia He

Keyword(s):

Renal Cell Carcinoma ◽

Nervous System ◽

T Cell ◽

Adverse Events ◽

Renal Cell ◽

Guillain Barre Syndrome ◽

Guillain Barré Syndrome ◽

Treatment Paradigm ◽

Triggering Factor ◽

Guillain Barré

Abstract Immunotherapy combinations have changed the treatment paradigm of advanced renal cell carcinoma (RCC). Notably, immunotherapy induces a new spectrum of immune-related adverse events (irAEs). Guillain–Barré syndrome (GBS) is a rare and potentially fatal nervous system irAE. The activation of T-cell is considered a triggering factor of GBS. We herein reported a case of GBS-like syndrome during treatment of tislelizumab and axitinib in a patient with RCC. To our knowledge, this is the first report of tislelizumab-related GBS.

Download Full-text